Results 301 to 310 of about 284,370 (314)

HER2-positive (HER2+) & HER2-negative (HER2−) targeted therapies

Vaishali Bambal, Seema S Rathore, Josephine J Leno Jenita, Priti Paul, Pankaj Kumar Singh, Vanaja Kenchappa   +5 more
openaire   +1 more source

HER2

2016
David G. Hicks, Susan C. Lester
openaire   +1 more source

HER2

2008
openaire   +2 more sources

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers

Cancer Cell, 2020
Dhivya R Sudhan, Ángel L Guerrero-Zotano, Helen H Won   +2 more
exaly  

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

Annals of Oncology, 2016
Julien Mazieres, Thomas Filleron, Federico Cappuzzo   +2 more
exaly  

HER2

2011
openaire   +1 more source

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Annals of Oncology, 2015
Giuseppe Giaccone
exaly  

Towards personalized treatment for early stage HER2-positive breast cancer

Nature Reviews Clinical Oncology, 2019
Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Carmine De Angelis   +2 more
exaly  

HER2 Testing Methods

Journal of the National Cancer Institute, 2000
openaire   +2 more sources

HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer

Cancer Treatment Reviews, 2012
Anne-Sophie Gauchez, Pierre-Jean Lamy
exaly